编辑丨于靖
9月13日,Akero Therapeutics宣布旗下药物Efruxifermin(EFX,曾用名AKR-001)在IIb期HARMONY研究中,可改善肝硬化前期非酒精性脂肪性肝炎(NASH)患者的肝纤维化并防止疾病恶化,Efruxifermin 28mg和50mg剂量组均达到了改善肝脏纤维化的主要终点以及多个次要终点...查看全文
chuminhua2021-08-26 14:55
8月25日,Lipocine公司宣布,其在研疗法LPCN 1144,在治疗非酒精性脂肪性肝炎(NASH)男性患者的2期概念验证临床试验LiFT中获得积极结果。LPCN 1144是一种口服的睾酮前药。NASH是全球肝衰竭和肝移植的主要原因,是非酒精性脂肪性肝病(NAFLD)的一种更晚期状态,可进展为肝硬化,最终发展为肝癌。...查看全文
SnowBall2020Q42021-02-05 22:17
$Lipocine(LPCN)$ 号称口服睾丸酮对于老年男性新冠患者有帮助,但是炒作第一波已经过了。口服治疗方案具体咋样还没有仔细研究。查看全文
$Lipocine(LPCN)$ 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] Filed: 2019-05-15 AccNo: 0001144204-19-026336 Size: 20 KB 网页链接
$Lipocine(LPCN)$ 8-K - Current report Filed: 2019-05-14 AccNo: 0001144204-19-025779 Size: 35 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Lipocine(LPCN)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2019-05-08 AccNo: 0001144204-19-024378 Size: 5 MB 网页链接
$Lipocine(LPCN)$ 8-K - Current report Filed: 2019-05-08 AccNo: 0001144204-19-024380 Size: 115 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Lipocine(LPCN)$ 8-K - Current report Filed: 2019-05-01 AccNo: 0001144204-19-022665 Size: 14 MBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Lipocine(LPCN)$ DEF 14A - Other definitive proxy statements Filed: 2019-04-30 AccNo: 0001144204-19-022112 Size: 959 KB 网页链接
$Lipocine(LPCN)$ 8-K - Current report Filed: 2019-04-11 AccNo: 0001144204-19-019156 Size: 1 MBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Lipocine(LPCN)$ 8-K - Current report Filed: 2019-04-03 AccNo: 0001144204-19-017898 Size: 32 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Lipocine(LPCN)$ 8-K - Current report Filed: 2019-03-28 AccNo: 0001144204-19-016413 Size: 9 MBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Lipocine(LPCN)$ 8-K - Current report Filed: 2019-03-27 AccNo: 0001144204-19-016088 Size: 40 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接